Go Pro
NASDAQ:SCYX

SCYNEXIS Q2 2026 Earnings Report

SCYNEXIS logo
$4.80 +0.40 (+9.00%)
As of 11:51 AM Eastern
This is a fair market value price provided by Massive. Learn more.

SCYNEXIS EPS Results

Actual EPS
$0.63
Consensus EPS
-$0.51
Beat/Miss
Beat by +$1.14
One Year Ago EPS
N/A

SCYNEXIS Revenue Results

Actual Revenue
$0.24 million
Expected Revenue
$0.08 million
Beat/Miss
Beat by +$155.00 thousand
YoY Revenue Growth
N/A

SCYNEXIS Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Monday, August 10, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

SCYNEXIS' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

SCYNEXIS Earnings Headlines

“Elon Is Not Showing This Publicly, But I Saw It”
Elon Musk quietly filed a patent for a new AI invention while attention focused on the SpaceX IPO. Jeff Brown, founder of Brownstone Research, calls it M.A.G.I. Venture capitalist Jason Calacanis, who turned $100,000 into $100 million from Uber's IPO, previewed the technology privately and called it the best selling product he has ever seen.tc pixel
SCYNEXIS Names Sanjay Subramanian as CFO
Scynexis Names Sanjay Subramanian CFO
See More SCYNEXIS Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SCYNEXIS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SCYNEXIS and other key companies, straight to your email.

About SCYNEXIS

SCYNEXIS (NASDAQ:SCYX) is a biotechnology company focused on developing and commercializing novel antifungal therapies for patients with fungal infections. Its lead product is BREXAFEMME (ibrexafungerp), an oral, non-azole antifungal designed to address certain vaginal and other fungal infections.

BREXAFEMME was approved by the U.S. Food and Drug Administration in 2021 for the treatment of vulvovaginal candidiasis, commonly known as a yeast infection. The product later received an additional U.S. approval for reducing the incidence of recurrent vulvovaginal candidiasis in adult and post-menarchal adolescent females. Ibrexafungerp belongs to a new class of antifungal agents known as triterpenoid antifungals.

SCYNEXIS has historically focused its research and development activities on addressing drug-resistant and difficult-to-treat fungal infections. The company’s commercial activities are primarily centered on the United States, while it has pursued collaborations and licensing arrangements to support the broader development and commercialization of ibrexafungerp.

View SCYNEXIS Profile